Changzhou Qianhong Biopharma CO.,LTD (002550.SZ)
CNY 5.68
(1.25%)
CNY 5.68
(1.25%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 210.32 Million CNY | -43.54% |
| 2022 | 372.53 Million CNY | -4.54% |
| 2021 | 390.23 Million CNY | 1.01% |
| 2020 | 386.35 Million CNY | -35.78% |
| 2019 | 601.64 Million CNY | -6.01% |
| 2018 | 640.11 Million CNY | 8.24% |
| 2017 | 591.4 Million CNY | -2.94% |
| 2016 | 609.33 Million CNY | 13.12% |
| 2015 | 538.67 Million CNY | 202.52% |
| 2014 | 178.06 Million CNY | 85.94% |
| 2013 | 95.76 Million CNY | 63.58% |
| 2012 | 58.54 Million CNY | -32.76% |
| 2011 | 87.07 Million CNY | -35.38% |
| 2010 | 134.75 Million CNY | -53.56% |
| 2009 | 290.18 Million CNY | 67.01% |
| 2008 | 173.75 Million CNY | 125.79% |
| 2007 | 76.95 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 181.25 Million CNY | -38.67% |
| 2024 Q3 | 277.37 Million CNY | 53.03% |
| 2024 Q1 | 295.55 Million CNY | 40.52% |
| 2023 Q3 | 258.94 Million CNY | -53.79% |
| 2023 Q2 | 560.32 Million CNY | 2.0% |
| 2023 FY | 210.32 Million CNY | -43.54% |
| 2023 Q1 | 549.34 Million CNY | 47.46% |
| 2023 Q4 | 210.32 Million CNY | -18.78% |
| 2022 Q4 | 372.53 Million CNY | -7.78% |
| 2022 Q2 | 455.07 Million CNY | 0.28% |
| 2022 FY | 372.53 Million CNY | -4.54% |
| 2022 Q1 | 453.81 Million CNY | 16.29% |
| 2022 Q3 | 403.95 Million CNY | -11.23% |
| 2021 Q3 | 261.5 Million CNY | 8.76% |
| 2021 Q1 | 245.88 Million CNY | -36.36% |
| 2021 FY | 390.23 Million CNY | 1.01% |
| 2021 Q4 | 390.23 Million CNY | 49.23% |
| 2021 Q2 | 240.44 Million CNY | -2.21% |
| 2020 Q2 | 502.18 Million CNY | 8.75% |
| 2020 Q4 | 386.35 Million CNY | 20.57% |
| 2020 Q1 | 461.77 Million CNY | -23.25% |
| 2020 FY | 386.35 Million CNY | -35.78% |
| 2020 Q3 | 320.43 Million CNY | -36.19% |
| 2019 Q1 | 617.31 Million CNY | -3.56% |
| 2019 Q4 | 601.64 Million CNY | -19.79% |
| 2019 Q3 | 750.13 Million CNY | 20.82% |
| 2019 Q2 | 620.85 Million CNY | 0.57% |
| 2019 FY | 601.64 Million CNY | -6.01% |
| 2018 Q3 | 733.56 Million CNY | 1.37% |
| 2018 FY | 640.11 Million CNY | 8.24% |
| 2018 Q2 | 723.65 Million CNY | 31.9% |
| 2018 Q1 | 548.62 Million CNY | -7.23% |
| 2018 Q4 | 640.11 Million CNY | -12.74% |
| 2017 Q3 | 449.05 Million CNY | -18.88% |
| 2017 Q1 | 551.29 Million CNY | -9.52% |
| 2017 FY | 591.4 Million CNY | -2.94% |
| 2017 Q2 | 553.55 Million CNY | 0.41% |
| 2017 Q4 | 591.4 Million CNY | 31.7% |
| 2016 Q2 | 502.24 Million CNY | -2.38% |
| 2016 FY | 609.33 Million CNY | 13.12% |
| 2016 Q1 | 514.49 Million CNY | -4.49% |
| 2016 Q3 | 480.27 Million CNY | -4.37% |
| 2016 Q4 | 609.33 Million CNY | 26.87% |
| 2015 Q4 | 538.67 Million CNY | 34.14% |
| 2015 Q3 | 401.57 Million CNY | 42.08% |
| 2015 FY | 538.67 Million CNY | 202.52% |
| 2015 Q1 | 140.74 Million CNY | -20.96% |
| 2015 Q2 | 282.64 Million CNY | 100.82% |
| 2014 Q3 | 97.62 Million CNY | 39.7% |
| 2014 FY | 178.06 Million CNY | 85.94% |
| 2014 Q4 | 178.06 Million CNY | 82.39% |
| 2014 Q2 | 69.88 Million CNY | 7.22% |
| 2014 Q1 | 65.18 Million CNY | -31.94% |
| 2013 Q3 | 59.54 Million CNY | 8.34% |
| 2013 Q4 | 95.76 Million CNY | 60.84% |
| 2013 FY | 95.76 Million CNY | 63.58% |
| 2013 Q1 | 51.96 Million CNY | -11.24% |
| 2013 Q2 | 54.95 Million CNY | 5.77% |
| 2012 Q3 | 95.84 Million CNY | -27.95% |
| 2012 FY | 58.54 Million CNY | -32.76% |
| 2012 Q1 | 54.91 Million CNY | -36.93% |
| 2012 Q2 | 133.03 Million CNY | 142.25% |
| 2012 Q4 | 58.54 Million CNY | -38.92% |
| 2011 Q2 | 64.47 Million CNY | -44.77% |
| 2011 FY | 87.07 Million CNY | -35.38% |
| 2011 Q1 | 116.74 Million CNY | -13.36% |
| 2011 Q3 | 76.05 Million CNY | 17.95% |
| 2011 Q4 | 87.07 Million CNY | 14.49% |
| 2010 Q3 | 156.82 Million CNY | -34.64% |
| 2010 FY | 134.75 Million CNY | -53.56% |
| 2010 Q2 | 239.93 Million CNY | 0.0% |
| 2010 Q4 | 134.75 Million CNY | -14.08% |
| 2009 FY | 290.18 Million CNY | 67.01% |
| 2009 Q4 | 290.18 Million CNY | 0.0% |
| 2008 FY | 173.75 Million CNY | 125.79% |
| 2007 FY | 76.95 Million CNY | 0.0% |